Catalogo dei prodotti della ricerca

ZORATTO, federica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.363
EU - Europa 555
AS - Asia 350
AF - Africa 8
SA - Sud America 5
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.284
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.361
IT - Italia 242
SG - Singapore 166
SE - Svezia 120
IN - India 86
CN - Cina 59
FI - Finlandia 44
DE - Germania 38
FR - Francia 19
GB - Regno Unito 16
UA - Ucraina 14
ID - Indonesia 13
RU - Federazione Russa 13
IR - Iran 11
RO - Romania 11
BG - Bulgaria 9
BE - Belgio 7
IE - Irlanda 6
GR - Grecia 5
TG - Togo 5
AR - Argentina 4
HK - Hong Kong 4
CH - Svizzera 3
ZA - Sudafrica 3
AT - Austria 2
CA - Canada 2
ES - Italia 2
KG - Kirghizistan 2
NL - Olanda 2
TW - Taiwan 2
AU - Australia 1
BD - Bangladesh 1
BR - Brasile 1
BT - Bhutan 1
DK - Danimarca 1
EU - Europa 1
HR - Croazia 1
JP - Giappone 1
LA - Repubblica Popolare Democratica del Laos 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
TH - Thailandia 1
TR - Turchia 1
Totale 2.284
Salva come PNG Salva come JPEG
Città #
Fairfield 225
Ashburn 123
Singapore 123
Chandler 93
Woodbridge 85
Houston 81
Seattle 72
Cambridge 71
Santa Clara 66
Wilmington 61
Ann Arbor 52
Rome 44
San Paolo di Civitate 39
Beijing 33
Princeton 33
Lawrence 25
Milan 25
Helsinki 24
New York 22
Boston 21
Plano 18
Millbury 15
San Diego 15
Jakarta 13
Andover 12
Boardman 12
Falkenstein 9
Norwalk 9
Sofia 9
Washington 8
Brussels 7
Des Moines 7
Dublin 6
Naples 6
Paris 6
West Jordan 6
Bühl 5
Dallas 5
Lomé 5
London 5
Pune 5
Athens 4
Dearborn 4
Federal 4
Fonte Nuova 4
Gurugram 4
Hong Kong 4
Los Angeles 4
Mantova 4
Moscow 4
Mumbai 4
Munich 4
Phoenix 4
Rizziconi 4
Rotondi 4
Bengaluru 3
Changsha 3
Florence 3
Frankfurt am Main 3
Gunzenhausen 3
Hefei 3
Pescara 3
Turin 3
Bishkek 2
Bologna 2
Castano Primo 2
Catania 2
Fasano 2
Fremont 2
Ghaziabad 2
Imola 2
Isfahan 2
Kansas City 2
Kottayam 2
Kunming 2
Lucera 2
Mannheim 2
Marino 2
Montepulciano 2
Muizenberg 2
New Delhi 2
Padova 2
Palermo 2
Paola 2
Perugia 2
Piazza Armerina 2
Redwood City 2
Romainville 2
Rozzano 2
Scunthorpe 2
Taipei 2
Thiene 2
Wuhan 2
Zurich 2
Angoulême 1
Barcelona 1
Berlin 1
Bern 1
Bonndorf 1
Boydton 1
Totale 1.649
Salva come PNG Salva come JPEG
Nome #
Breast metastasis and lung large-cell neuroendocrine carcinoma: first clinical observation 119
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) 118
Internet addiction in adolescence: neurobiological, psychosocial and clinical issues 102
Breast adenomyoepithelioma: a case report with malignant proliferation of epithelial and myoepithelial elements 97
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. 85
Current approach in the treatment of hepatocellular carcinoma. 84
Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study 80
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab. a real-life multicentre study 79
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 75
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 74
Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. 73
Comparative Analysis of Regorafenib and Trifluridine/Tipiracil in Later-Line Refractory Metastatic Colorectal Cancer: A Real-Life Multicenter Retrospective Study 69
Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis 69
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer. The multicenter “SLAVE” study 65
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 64
Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression ≥ 50% and their relationship with clinical outcomes 63
Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study 61
Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. 61
Nonpegylated liposomal doxorubicin (nPLD) in neoadjuvant treatment of local advanced breast cancer (LABC) patients (pts) 58
Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma 52
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study 50
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 50
Reduced adolescent risk-assessment and lower nicotinic beta-2 expression in rats exposed to nicotine through lactation by forcedly drinking dams 49
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%. A multicenter study with external validation 49
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 48
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study 47
null 45
A real-life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second-line therapy 45
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 45
Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer 44
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer 40
From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors 36
398P Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment 29
null 29
P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis 25
Treatment settings and outcomes with Regorafenib and Trifluridine/Tipiracil at third-line treatment and beyond in metastatic colorectal cancer: a real-world multicenter retrospective study 24
Incidence of chemotherapy (CT) induced amenorrhea in premenopausal patients (pts) with breast cancer (BC) following adjuvant anthracycline (A), cyclophosphamide (C), and taxane (T) 23
null 20
Radiological and pathological complete response in a young patient locally advanced her2 breast cancer after neoadjuvant treatment with trastuzumab and non-pegylated liposomal doxorubicin (nPLD) 20
Efficacy, safety and cost-effectiveness (ce) analysis of lenograstim (l) versus pegfilgrastim (p) in management of chemotherapy related neutropenia (crn) in non metastatic breast cancer (bc) patients 19
null 18
null 15
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study 14
Non pegylated liposomal doxorubicin (npld) in neoadjuvant treatment of local advanced breast cancer (labc) 14
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis 13
Efficacy of regorafenib and trifluridine/tipiracil according to extended RAS evaluation in advanced metastatic colorectal cancer patients: a multicenter retrospective analysis 13
P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis 12
Survival benefit with regorafenib and/or trifluridine/tipiracil sequencing to rechallenge with anti-EGFR-based third-line regimens in metastatic colorectal cancer: A multicenter retrospective real-world subgroups comparison 10
73P Efficacy outcomes in ≥70-year-old or younger patients receiving regorafenib-to-trifluridine/tipiracil sequence or vice versa for refractory metastatic colorectal cancer: Findings from the multicenter retrospective “ReTrITA” study 8
Safety of extended interval dosing immune checkpoint inhibitors. A multicenter cohort study 7
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 7
529P Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective “ReTrITA” study 5
Totale 2.421
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.225
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.225
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020265 0 0 0 0 0 44 52 46 55 35 21 12
2020/2021247 10 17 6 4 7 8 18 33 17 24 32 71
2021/2022373 5 6 41 20 52 16 10 38 27 17 83 58
2022/2023493 97 120 32 21 40 36 13 47 54 4 22 7
2023/2024362 18 39 31 31 47 66 5 30 12 52 10 21
2024/2025314 18 47 51 69 84 45 0 0 0 0 0 0
Totale 2.421